PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios.
Saved in:
| Title: | PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios. |
|---|---|
| Authors: | Suh, K1, Carlson, JJ1, Garrison, LP1 |
| Source: | Value in Health. May2016, Vol. 19 Issue 3, pA62-A63. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
